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Local generation of hydrogen for enhanced
photothermal therapy
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By delivering the concept of clean hydrogen energy and green catalysis to the biomedical
field, engineering of hydrogen-generating nanomaterials for treatment of major diseases
holds great promise. Leveraging virtue of versatile abilities of Pd hydride nanomaterials in
high/stable hydrogen storage, self-catalytic hydrogenation, near-infrared (NIR) light
absorption and photothermal conversion, here we utilize the cubic PdH0.2 nanocrystals for
tumour-targeted and photoacoustic imaging (PAI)-guided hydrogenothermal therapy of
cancer. The synthesized PdH0.2 nanocrystals have exhibited high intratumoural accumulation
capability, clear NIR-controlled hydrogen release behaviours, NIR-enhanced self-catalysis bio-
reductivity, high NIR-photothermal effect and PAI performance. With these unique properties
of PdH0.2 nanocrystals, synergetic hydrogenothermal therapy with limited systematic toxicity
has been achieved by tumour-targeted delivery and PAI-guided NIR-controlled release of bio-
reductive hydrogen as well as generation of heat. This hydrogenothermal approach has
presented a cancer-selective strategy for synergistic cancer treatment.
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Hydrogen gas (H2), as a kind of endogenous gas, is not onlyan important energy source, but also exhibits significantphysiological/pathological regulation functions1. As early
as 1975, hydrogen gas has been found to be able to treat cancers2.
In 2007, hydrogen was confirmed to be a therapeutic antioxidant
that can selectively reduce cytotoxic oxygen radicals induced by
ischaemia–reperfusion and inflammation3,4. In the past 10 years,
hydrogen gas has been testified to practicably treat many diseases,
including cancer, diabetes, stroke, atherosclerosis, Parkinson’s
disease, Alzheimer’s disease, arthritis, dermatitis, colonitis,
hepatitis, pancreatitis, myocardial infarction and tristimania1–12.
The selective anti-oxidation profile of hydrogen gas is a com-
monly accepted mechanism for hydrogen therapy. As to cancer,
both increase and decrease of rightly overexpressed reactive
oxygen species (ROS) level in cancer cells could break the redox
homoeostasis and bring redox stress, causing cancer cell damage
and apoptosis13,14. The mechanism of hydrogen therapy for
cancer could be related to the influence of hydrogen on intratu-
moural ROS level by virtue of its anti-oxidation. Besides good
biomedical applicability, high bio-safety of hydrogen gas has also
been widely confirmed15–22. Therefore, hydrogen therapy receives
increasing attention with progressive clinical trials23–29, and is
being accepted as a promising therapeutic method30.
Hydrogen gas has some special properties, including high
aimless bio-diffusibility derived from small molecular size,
nonpolarity and low solubility (1.6 ppm) at the physiological
conditions. Therefore, the traditional administration routes,
such as inhalation of hydrogen gas, oral intake of hydrogen-
rich water and injection of hydrogen-rich saline, have unde-
sirable performance for disease-targeted delivery and con-
trolled release of hydrogen, frequently leading to limited
therapeutic efficacy7–12. How to realize the effective storage,
targeted delivery and controlled release of hydrogen is vitally
important to enhance hydrogen therapeutic efficacy, but
it still remains challenging at present31,32. Nanomaterial pro-
vides a promising platform to overcome this challenge5,6,33–35.
Noticeably, Pd nanocrystal is an excellent hydrogen storage
material and ideal catalyst for hydrogenation reaction36–43,
potentially promoting hydrogen therapy outcomes. In this
work, we design the Pd hydride (PdH0.2) nanocrystals as a
multifunctional hydrogen carrier and Pd-similar self-catalyst
to achieve the tumour-targeted delivery and controlled release
of bio-reductive hydrogen.
The combination of gas therapy and traditional therapy,
such as chemotherapy and radiotherapy, has proved to have
synergetic therapy effects44–52. Pd nanomaterials with varied
morphologies have been demonstrated as excellent photo-
thermal therapy (PTT) and photoacoustic imaging (PAI) agents
with high near-infrared (NIR)-photothermal conversion effi-
ciencies and good biocompatibility53–59. Herein, we design the
hydrogenated Pd nanocrystals to realize the combined hydro-
genothermal therapy. Unexpectedly, we discovered that the
hydrogenothermal therapy not only has a synergetic anticancer
effect, but also potentially protects normal cells from hyper-
thermia damage.
In this work, we synthesize a 30 nm cubic Pd nanocrystal to
achieve the passive tumour targeting by the enhanced perme-
ability and retention (EPR) effect. Importantly, considerable
hydrogen could be incorporated and stabilized within the lattice
of Pd crystals to form Pd hydride (Fig. 1a). The hydrogenation
of Pd nanocrystals results in the significant enhancement of
NIR absorption, which enables the PAI-guided release of bio-
reductive hydrogen as well as photothermal therapy. The
tumour-targeted delivery and PAI-guided release of hydrogen
and the generated heat demonstrate significantly enhanced
anticancer efficacy.
Results
Synthesis and characterization of Pd and PdH0.2 nanocrystals.
It has been well proved that Pd, especially in nanoscale, has the
excellent capacity of hydrogen storage as well as thermal stability
after incorporation of hydrogen into the lattice of Pd. Therefore,
the nano-sized Pd crystals were synthesized and used as the
hydrogen host to form PdH0.2. From Fig. 1b, c, it could be found
that synthesized Pd nanocrystals exhibited cubic morphology,
uniform particle size and good dispersion owing to the surface
coating of poly(vinyl pyrrolidone) (PVP; Supplementary Fig. 1),
and PdH0.2 completely inherited/unchanged these features in
morphology and size. Such a small size and good dispersion are
favourable for passive tumour targeting60,61. From X-ray dif-
fraction (XRD) data in Fig. 1d, it could be found that both syn-
thesized Pd and PdH0.2 were typical face-centred cubic crystals,
and the unit cell parameters of Pd became a little bigger after
hydrogenation, suggesting that hydrogen atoms had been incor-
porated into the lattice of Pd crystals forming Pd hydride36.
Compared to Pd, the ultraviolet (UV)-zone absorption of PdH0.2
(Fig. 1e) became weaker but the VIS−NIR-zone absorption of
PdH0.2 became stronger, enabling the PAI-guided release of
hydrogen and enhanced photothermal therapy.
Behaviour and mechanism of NIR-responsive hydrogen
release. Furthermore, the process and mechanism of NIR-
responsive hydrogen release from PdH0.2 were investigated by
UV, XRD and Pt-microelectrode methods. According to the
increase-to-decrease transformations of UV characteristic peak
intensity (shown by up/down arrows in Supplementary Fig. 2 and
Fig. 2a) under the continuous irradiation of 808 nm light, it was
inferred that there could be a critical intermediate phase (repre-
sented by PdHc) during dehydrogenation of PdH0.2. According to
the Beer–Lambert law, the hydrogen release percentage of PdH0.2
nanocrystals could be calculated (Supplementary Equations 7, 8),
and the hydrogen release process could be quantitatively and
intuitively demonstrated as shown in Fig. 2b. It was uncovered
that the rate of the hydrogen release from PdH0.2 nanocrystals
increased first and then decreased under the NIR irradiation,
where there was a critical point (Fig. 2b). Such a dehydrogenation
process is different from general drug release, but similar to the
photochemical gas-releasing decomposition of CO prodrug pre-
viously reported by us, exhibiting a typical profile of photo-
chemical reaction62. By respective irradiation at different power
densities (0.2, 0.5, 1.0W cm−2), it could be found that PdH0.2 was
responsive to NIR light in a power density-dependent manner
(Fig. 2b). Higher power densities of NIR light caused faster
hydrogen release from PdH0.2. Therefore, it is feasible to control
the rate and amount of hydrogen release by adjusting the power
and duration of NIR irradiation.
Moreover, the Pt-microelectrode method was used to further
quantitatively detect the hydrogen release from PdH0.2 nanocrys-
tals in real time. Unexpectedly, large amounts of hydrogen could
be detected by the Pt-microelectrode once PdH0.2 nanocrystals
were injected into pure degassed water with the hydrogen
microelectrode (50 μm in diameter), and then the detected
hydrogen concentration decreased gradually in the absence of
NIR irradiation (Fig. 2c). It was thought that the nano-sized Pt-
microelectrode tip quickly adsorbed PdH0.2 nanocrystals and
seized the active hydrogen atoms on the surface of PdH0.2
nanocrystals (as shown by green interface), and then consumed
the adsorbed hydrogen gradually (as indicated by grey arrow).
When the Pt-microelectrode was irradiated by NIR laser
immediately after the addition of PdH0.2 nanocrystals, the
detected hydrogen amount was obviously less compared to the
case of no NIR irradiation (Fig. 2c), suggesting that hydrogen
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escaped from PdH0.2 nanocrystals under the NIR irradiation
which led to less detectable interface active hydrogen (as shown
by blue arrows) till the completion of hydrogen release (about 50
min of NIR irradiation). It could also be found that higher NIR
power density resulted in less hydrogen detection (Fig. 2c),
indicating that higher power density of NIR irradiation could
cause faster hydrogen release from PdH0.2 nanocrystals in
accordance with above-mentioned UV monitoring results. Taking
the case of no NIR irradiation as background for subtraction, the
NIR-triggered release of hydrogen from PdH0.2 nanocrystals
could be represented to distinctly demonstrate the NIR-triggered
hydrogen release behaviours of PdH0.2 nanocrystals, as shown in
Fig. 2d. In addition, the XRD technique was also used to in-time
track the change in the crystal structure of PdH0.2 under the
irradiation of NIR light. From XRD data (Fig. 2e), it could be
observed that XRD peaks of PdH0.2 were gradually shifted to Pd
during the NIR irradiation. According to the Bragg equation, the
unit cell parameter a was calculated (see Methods), as shown in
Fig. 2f. It could be found that the unit cell parameter a of PdH0.2
gradually reduced to approach that of Pd during the continual
NIR irradiation (Fig. 2f), indicating the NIR-responsive release of
hydrogen from the lattice of PdH0.2. Furthermore, higher power
of NIR irradiation caused sharper shrinkage of crystalline lattice,
reflecting quicker release of hydrogen (Fig. 2f, Supplementary
Fig. 3) in accordance with the above-mentioned UV/microelec-
trode tracing results.
Bio-reductivity of NIR-responsive PdH0.2 nanocrystals. The
bio-reductivity of released hydrogen from PdH0.2 and the effect of
NIR irradiation were further investigated by methylene blue
(MB), which was an oxidative probe for active hydrogen detec-
tion. Generally, MB needs to be combined with Pt nanoparticles
as catalyst for hydrogen detection63. However, PdH0.2 nano-
crystals could play the Pt-similar catalyst role (called self-catalyst)
to assist the hydrogenation reaction (namely assist MB for
hydrogen detection), which also means that the hydrogen
released from PdH0.2 has the enhanced reductivity compared with
free hydrogen gas (Fig. 3a). According to the hydrogen detection
mechanism of the MB probe (Supplementary Fig. 4), the blue
colour fading means the reduction of MB, reflecting the bio-
reductivity of released hydrogen or hydrogen gas. Thus, the
released reductive hydrogen could be quantified according to the
change in the absorbance of the characteristic absorption peak of
MB at 664 nm and the plotted standard curve by virtue of the
Beer–Lambert law (Supplementary Fig. 5). The hydrogen-
incorporation capacity of PdH0.2 was calculated to be about 0.2
mol mol−1, determining the actual molecular formula of syn-
thesized Pd hydride to be PdH0.2. Moreover, hydrogen detection
results indicated that the H2-rich water (self-made by blowing H2
gas into deionized water as shown in Supplementary Fig. 6) was
discovered to be able to slowly reduce MB to a certain extent in
the absence of any catalyst (Fig. 3a). By comparison with free
hydrogen gas, PdH0.2 nanocrystals exhibited higher reductivity
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Fig. 1 Synthesis and characterization of PdH0.2 nanocrystals. a Schematic illustration of the synthesis and NIR-controlled release of bio-reductive hydrogen
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without NIR irradiation (Fig. 3a, Supplementary Fig. 6, 7) owing
to the existence of hydrogen atoms on the crystal surface, con-
firming that PdH0.2 was remarkably enhanced under the NIR
irradiation (Fig. 3a), owing to the NIR-responsive hydrogen
release and the self-catalysis function of PdH0.2. In addition, the
stability of PdH0.2 nanocrystals in phosphate-buffered saline
(PBS) was further evaluated by in-time UV monitoring for 48 h in
the absence of NIR irradiation. It was found that the UV spec-
trum was barely changed within 48 h (Supplementary Fig. 8),
indicating a high stability of synthesized PdH0.2 under the present
conditions in favour of NIR-controlled release of hydrogen. Such
a relatively high stability of PdH0.2 nanocrystal was possibly
attributed to its low chemical potential owing to its low
hydrogen-incorporating capacity64,65. The bio-reductivity of
PdH0.2 was further checked in a cell line model using the MB
probe. As shown in Fig. 3b, PdH0.2 still exhibited the intracellular
time-dependent bio-reductivity (Supplementary Fig. 9) similar to
the case of the simulated body fluid. The NIR irradiation could
similarly excitate PdH0.2 to release the bio-reductive hydrogen in
cells and consequently enhanced the bio-reductivity of PdH0.2.
Both results in simulated body fluid and cells confirmed that
PdH0.2 nanocrystals had bio-reductivity, and it could be enhanced
under the NIR irradiation.
The confirmed NIR-controlled bio-reductivity of PdH0.2
nanocrystals encouraged us to study their application for disease
treatment. According to a previous study, Ohta and colleagues3
found that the administration of H2 could selectively reduce
cytotoxic ROS, such as hydroxyl radical, which are generally
overexpressed in tumour cells. The anti-oxidative ability of
intracellular administrated H2 is one of the main mechanisms for
hydrogen therapy of inflammation-related diseases. Therefore,
the effect of PdH0.2 nanocrystals on intracellular ROS levels in
cancer and normal cell models was investigated in order to
evaluate its potential for cancer therapy. A ROS assay kit based on
the dichlorodihydrofluorescein diacetate (DCFH-DA) probe was
used to measure the change of intracellular ROS levels after
treatment with PdH0.2 nanocrystals without/with the NIR
irradiation. From Fig. 3c, d, it could be discovered that the
administration of PdH0.2 nanocrystals immediately caused
remarkable decrease of the intracellular ROS level in both cancer
and normal cell models in a concentration-dependent way,
further confirming the intracellular bio-reductivity of PdH0.2.
Subsequently, the intracellular ROS levels in two cell models
gradually increased (about 40 min and 120 min for cancer and
normal cells, respectively), then decreased (150−300 min and
400 min for cancer and normal cells, respectively). Cancer cells
were more sensitive to PdH0.2 nanocrystals than normal cells,
possibly owing to the higher initial ROS level in cancer cells. The
first increase of intracellular ROS level could be attributed to
the stress response of cells to PdH0.2 nanocrystals, while the
consequent decrease of intracellular ROS level should be due to
the gradual release of bio-reductive hydrogen from PdH0.2
nanocrystals as the NIR irradiation could accelerate this process
(Fig. 3c, d). It is worth noting that there was not only simple
antagonistic effect between ROS and bio-reductive hydrogen
from PdH0.2, but there were also differences in the ROS response
to hydrogen and the redox homoeostasis of different cells.
Remarkably higher redox stress was suppressed on cancer cells
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compared to normal cells. The reduction effect of PdH0.2
nanocrystals induced the intracellular ROS level to quickly
decline, subsequently causing the rebound of ROS due to the
redox homoeostasis capability of cells. Owing to the relatively
higher ROS level in cancer cells, the initial ROS loss in cancer
cells was higher and the subsequent ROS rebound was also
intenser/higher than that in normal cells. The highly over-
expressed ROS in cancer cells was hardly eliminated to the
normal level, leading to the oxidative stress remarkably (Fig. 3c).
However, the rebound of ROS in normal cells was much slower
and slighter so that bio-reductive PdH0.2 nanocrystals could easily
scavenge the weaker oxidative stress and pull ROS back to the
normal level (Fig. 3d). The thermal generation from PdH0.2/Pd
nanocrystals under the NIR irradiation would cause inflamma-
tion and induce cell apoptosis66–70. As to cancer cells, both
hydrogen and heat increased the ROS level and therefore the
hydrogenothermal combination was expected to induce the
synergetic enhancement for inhibiting cancer cells. However, as
to normal cells, the residual bio-reductive capacity of PdH0.2
nanocrystals could persistently scavenge the ROS generated from
heat after elimination of the weak oxidative stress from the redox
homoeostasis, in favour of protecting normal cells from the
heating damage. Based on the selective enhancement of ROS
in cancer cells and the effective scavenging of upregulated ROS
in cancer cells, PdH0.2 nanocrystals could induce the apoptosis of
cancer cells and reduce heating damage toward normal cells.
NIR-photothermal effect and PAI performance. Besides
hydrogen therapy, PdH0.2 nanocrystals could also be developed
for combined hydrogenothermal therapy owning to their NIR
absorption property (Fig. 1e). First, the NIR-photothermal effect
of PdH0.2 nanocrystals was investigated under the 808 nm laser
irradiation. From Fig. 4a, it could be found that the aqueous
solution of PdH0.2 nanocrystals (40 μg mL−1) exhibited a clear
NIR-photothermal effect, which was positively related to the
power density and duration of NIR irradiation. Typically, the
solution temperature increased by 13 °C after NIR irradiation at
the power density of 0.5W cm−2 for 10 min, which was sufficient
to kill cancer cells. By comparison with Pd nanocrystals, PdH0.2
nanocrystals exhibited relatively stronger NIR-photothermal
effects, owing to the more intensive NIR absorption (Fig. 1e).
Furthermore, the photothermal conversion efficiencies (η) of
PdH0.2 and Pd nanocrystals were measured (Fig. 4b) to be as high
as 62.9% and 64.8%, respectively. Moreover, the NIR-
photothermal effect of PdH0.2 nanocrystals in the 4T1 tumour
model was checked. At 1 h after tail vein injection of PdH0.2
nanocrystals (2 mgmL−1, 100 μL), the mice were anesthetized,
and then the tumours were irradiated by NIR light at the power
density of 1.0W cm−2 for 6 min (pointed by red arrows in
Fig. 4c). The change of temperature at the tumour site was
monitored using a thermal imaging camera. As shown in Fig. 4c,
it was observed that the PBS control group showed about 8.5 °C
of temperature increase at the tumour site, while the PdH0.2 and
Pd groups exhibited about 21 °C and 16.5 °C of temperature
increase, suggesting that PdH0.2 and Pd nanocrystals could
effectively accumulate in the tumour via a passive targeting way
and had enough high NIR-photothermal effect in vivo for ther-
mal therapy of cancer.
Furthermore, PAI technique was applied to confirm the
intratumoural accumulation of PdH0.2 nanocrystals and its PAI
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performance for therapy guidance. PdH0.2 nanocrystals were
firstly confirmed to have excellent PAI performance in the PBS
(Supplementary Fig. 10). Moreover, as shown in Fig. 4d−f,
compared with pre-injection (0 h), the intratumoural PAI signal
quickly increased at 1 h post vein injection of PdH0.2 nanocrystals
and reached the maximum at 2 h, and then maintained at a
relatively high level for 48 h. It is indicated that PdH0.2
nanocrystals could effectively accumulate and stably resorted in
the tumour in accordance with the above-mentioned NIR-
photothermal imaging results, and could also have excellent PAI
performance in favour of tumour localization and therapy
guidance. Moreover, the biodistribution and intratumoural
accumulation of PdH0.2 nanocrystals 48 h after vein injection
were further investigated by the inductively coupled plasma (ICP)
measurement. From Fig. 4f, it could be found that the
intratumoural accumulation of PdH0.2 nanocrystals at 2 h post
injection is quite significant besides that associate with liver and
spleen in support of passive tumour targeting by EPR effect.
Nevertheless, no visible tissue toxicity to liver and spleen could be
observed after treatment for 3 weeks (Supplementary Fig. 11).
In vitro hydrogenothermal therapy efficacies and mechanisms.
Based on the above-confirmed bio-reductivity of NIR-
responsively released hydrogen and NIR-photothermal effects of
PdH0.2 nanocrystals, combined hydrogenothermal therapy of
cancer was worthy of expectation and was further investigated
in vitro and in vivo. Firstly, the cytotoxicities of PdH0.2 and Pd
nanocrystals against cancer (4T1, B16-F10, HeLa cells) and nor-
mal (HEK-293T cells) cells were investigated and compared
in vitro. From Supplementary Fig. 12a, e, i, m, PdH0.2 nano-
crystals without the NIR irradiation generally exhibited the
remarkable concentration- and time-dependent cytotoxicity
against various cancer cells (Supplementary Fig. 12a, e, i), but
insignificant cytotoxicity to normal cells in the investigated
concentration range (0−200 μg mL−1) in spite of incubation time
(Supplementary Fig. 12 m, Fig. 5a, b). It is suggested that PdH0.2
could selectively kill cancer cells rather than normal cells only by
hydrogen therapy, possibly owing to the difference in the effects
of the bio-reductive hydrogen from PdH0.2 nanocrystals on the
intracellular ROS levels in cancer and normal cells as mentioned
above (Fig. 3). In order to investigate thermal therapy effect, we
applied Pd nanocrystals plus NIR irradiation as a control. As
shown in Supplementary Fig. 12b, f, j, n, thermal therapy by Pd
nanocrystals plus NIR irradiation had no selectivity to cell types,
which killed both cancer and normal cells in a NIR power
density-dependent and concentration-dependent way. However,
the combined hydrogenothermal therapy by PdH0.2 nanocrystals
plus NIR irradiation still exhibited remarkably an anticancer
selectivity (Supplementary Fig. 12c, g, k, o). By comparison, the
combined hydrogenothermal therapy by PdH0.2 nanocrystals plus
NIR irradiation remarkably enhanced the anticancer efficacies of
hydrogen therapy or/and thermal therapy to achieve a synergetic
anticancer effect (Supplementary Fig. 12d, h, l), but had no
remarkable cytotoxicity to HEK-293T normal cells (Supplemen-
tary Fig. 12p). Such cancer-selective, anticancer synergetic and
normal-protective effects of hydrogenothermal therapy by PdH0.2
nanocrystals could be valuable for high-efficacy and low-toxicity
cancer treatment.
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In order to further clarify the mechanism of hydrogenothermal
therapy, we investigated cell energy metabolism behaviours in
addition to the alteration of ROS level in cancer and normal cells
(Fig. 5c, d). An illustration (Supplementary Fig. 14) was also
drawn to elucidate the mechanism. It could be found that PdH0.2
nanocrystals without NIR irradiation did damage to the
mitochondrial metabolism function of cancer cells (ATP↓, Fig. 5c,
Supplementary Fig. 13) which was reflected by oxygen consump-
tion rate (OCR) so that cancer cells had to resort to more non-
mitochondrial metabolism which was reflected by extracellular
acidification rate (ECAR), and had depressed maximum respira-
tion and increased spare respiratory capacity (Supplementary
Fig. 13a, b). The damage to the mitochondria of cancer cells was
possibly attributed to the increase of intracellular ROS level
(Fig. 3c). On the other way, the ROS level in normal cells could be
easily normalized (Fig. 3d) so that PdH0.2 nanocrystals had no
obvious damage to mitochondrial function (ATP↑, Fig. 5d) and
insignificant influence on energy metabolism of normal cells
(OCR/ECAR→). The treatment with Pd nanocrystals under NIR
irradiation was used to represent only thermal effect. It could be
found that only thermal therapy always caused the overall
inhibition to cell energy metabolism in both cancer and normal
cells (Fig. 5c, d). By combination of hydrogenothermal therapy
using PdH0.2 nanocrystals, the overall energy metabolism of
cancer cells was blocked synergistically by hydrogen and heat
(Fig. 5c, d), which resulted in enhanced cancer cell apoptosis
(Fig. 5a). However, the strong ROS-scavenging effect of hydrogen
maintained the balance of ROS level in normal cells and
recovered their energy metabolism capability from heating
damage (Fig. 5b−d, Supplementary Fig. 13c, d). Therefore,
hydrogenothermal combination could selectively protect normal
cells and enhance anticancer effect (Supplementary Fig. 14).
In vivo hydrogenothermal therapeutic efficacies. To further
investigate in vivo hydrogenothermal therapeutic efficacy, we first
injected healthy mice (about 20 g) with different concentrations
of 100 μL PdH0.2 nanocrystals (2−100 mgmL−1, equal to 10
−500 mg kg−1) to determine the safe dose. No mouse died after
intravenous injection of PdH0.2 in the present concentration
range (10−500 mg kg−1) for 8 days. The blood test results also
indicated that PdH0.2 had not affected the liver and kidney
functions of treated mice obviously even at the highest injection
dose of 500 mg kg−1 (Supplementary Fig. 15). However, PdH0.2
could not bring visible abnormality of several blood indicators
such as red blood cells (RBC), white blood cells (WBC), hae-
moglobin (HGB), means corpuscular haemoglobin concentration
(MCHC), lymphocytes percentage (LYM), means corpuscular
volume (MCV), haematocrit (HCT), and red blood cell volume
distribution width (RDW-SD) until the dose of PdH0.2 went up to
500 mg kg−1 (Supplementary Fig. 16). It could be concluded
that the safe dose of PdH0.2 nanocrystals was not lower than
250 mg kg−1. Therefore, the present injection dose of 10 mg kg−1
for cancer therapy should be safe enough. The 4T1 tumour model
was established by subcutaneous injection of murine 4T1 breast
cancer cells into the hind limb space of BALB/c (4 weeks old)
mice. Mice were randomly divided into six groups: the PBS group
(blank control), the PBS+NIR group (NIR control), the Pd−NIR
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group (Pd control), the Pd+NIR group (thermal therapy group),
the PdH0.2−NIR group (hydrogen therapy group) and the PdH0.2
+NIR group (hydrogenothermal therapy group). As to NIR
irradiation groups, the tumour site of mouse was exposed to NIR
light (0.5 or 1W cm−2) at fixed time points (days 1, 2, 3, 8) after
1 h post injection of PBS, Pd or PdH0.2 nanocrystals (100 μL, 10
mg kg−1), as illustrated in Fig. 6a. From Fig. 6b (0.5W cm−2) and
Supplementary Fig. 17 (1W cm−2), neither only NIR irradiation
nor only Pd nanocrystals without NIR irradiation affected the
tumour growth, and both the hydrogen therapy group
(PdH0.2−NIR) and the thermal therapy group (Pd+NIR) caused
slight inhibition to the tumour growth. The most noticeable was
that the combined hydrogenothermal therapy group (PdH0.2+
NIR) generated considerably remarkable tumour inhibition effect
during the 22-day observation (Fig. 6b). It was also worth noti-
cing that even though no more NIR irradiation was provided for
thermal therapy after 8 day post injection, the tumours were still
stably inhibited at a very small volume in the later period (days 8
−22), indicating that later hydrogen therapy could maintain a
good tumour inhibition efficacy owing to the super-sustained
hydrogen release profile of PdH0.2 nanocrystals (Fig. 3a). Com-
pared with only hydrogen therapy and only thermal therapy,
combined hydrogenothermal therapy exhibited a synergetic
anticancer effect (Fig. 6b) in accordance with the above-
mentioned in vitro cytotoxicity results (Fig. 5a, b). After
22 days post injection, the tumours and main organs of mice were
extracted to further confirm the hydrogenothermal therapy out-
come and tissue compatibility of PdH0.2 nanocrystals (Fig. 6c, d).
It was found that the differences in the mouse body weight among
various treatment groups were insignificant (Supplementary
Fig. 18 and 19). In addition, the histopathological evaluation
by the haematoxylin and eosin (H&E) staining method
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(Supplementary Fig. 11) indicated that all treatment groups did
not do visible damage to main organs (heart, liver, spleen, lung
and kidney), reflecting good tissue compatibility of PdH0.2
nanocrystals.
Next, we further investigated another tumour model (B16-F10
melanoma tumour) which was established by subcutaneously
injecting B16-F10 melanoma cancer cells into the hind limb space
of BALB/c nude mice (4 weeks old). Relatively lower laser power
density of 0.5W cm−2 was used to irradiate the B16-F10 tumours
owing to higher self-photothermal effect of melanoma tumour
compared to 4T1 tumour. Even so, more obvious photothermal
therapy outcomes were achieved (PBS+NIR and Pd+NIR
groups, Fig. 6e, f). Melanoma tumour seems to be more sensitive
to individual hydrogen therapy compared to 4T1 tumour
(PdH0.2−NIR groups, Fig. 6e, f). Compared with only hydrogen
therapy and only thermal therapy, combined hydrogenothermal
therapy also exhibited a synergetic anticancer effect to B16-F10
melanoma tumour-bearing mice (Fig. 6e) in accordance with the
above-mentioned outcome of 4T1 breast tumour-bearing mouse
therapy (Fig. 6b). The tumour extraction results after 15-day
treatment further conformed the remarkable hydrogenothermal
therapy outcome of PdH0.2 nanocrystals (Fig. 6f).
Discussion
In this work, we developed PdH0.2 nanocrystals for the tumour-
targeted delivery and controlled release of bio-reductive hydrogen
for hydrogenothermal therapy of cancer. PdH0.2 nanocrystals
displayed a broad UV−to−NIR absorption spectrum with a
stronger NIR absorption compared with the same size of Pd
nanocrystals, and exhibited the enhanced NIR-photothermal
effect, enabling the PAI-guided NIR-controlled release of
hydrogen and the generated heat. PdH0.2 nanocrystals exhibited
the selective and synergetic effects for hydrogenothermal therapy
in vitro and in vivo. Of note, by combined hydrogenothermal
therapy, the side effect of pure thermal therapy to normal cells/
tissues could be reduced while its positive effect to cancer cells
could be enhanced by the controlled administration of bio-
reductive hydrogen. This broad-spectrum and safe therapy
strategy could be highly desired for clinical applications. Such
homoeostatic regulation function of bio-reductive hydrogen is
similar to several typical therapeutic gases such as NO and CO,
which could be explained from the standpoint of cell energy
metabolism71, while hydrogen gas is highly bio-safe without
obvious poisoning effect15–22.
Methods
Chemicals. Sodium tetrachloropalladate (Na2PdCl4), PVP, potassium bromide
(KBr), L-ascorbic acid (AA), MB and sodium borohydride (NaBH4) were pur-
chased from Sigma-Aldrich. The CCK-8 kit and the ROS assay kit were purchased
from Beyotime Biotechnology Co., Ltd. All other agents used were of the highest
commercial grade available.
Synthesis of Pd nanocrystals. The Pd nanocrystals were synthesized by a facile
redox route. Firstly, an aqueous solution (11 mL) of PVP (106.4 mg), AA (60 mg),
KBr (301 mg) and Na2PdCl4 (56.31 mg) was heated at 80 °C under magnetic
stirring for 3 h, and then cooled to room temperature. Then, the Pd nanocrystals
were collected and purified using Amicon hyperfiltration tubes (molecular weight
cut-off 100 kDa, Millipore) by 30 min of centrifugation at 1492 × g and three-time
washing. Finally, the obtained Pd nanocrystals were dispersed in 10 mL of deio-
nized water and stored in the dark for following use.
Synthesis of PdH0.2 nanocrystals. The 2 mL Pd nanocrystals were injected into a
vial of 20 mL and sealedt with a rubber stopper. Then, 100 mg NaBH4 were taken
in another vial and sealed with a rubber stopper. Two vials were connected with a
capillary. A needle was inserted connected with 1 mL syringe into the first vial for
the connection to the atmosphere. Then, pH= 5 sulphuric acid solution was
injected into the second vial containing NaBH4 using a syringe of 2 mL. NaBH4 in
the presence of acidic solution can produce hydrogen gas, so that hydrogen gas
could slowly drum into the Pd nanocrystal solution. After 15 min, the needle and
capillaries were removed, the vial of PdH0.2 nanocrystals was sealed and stored in
the dark for the further use.
Characterization of Pd and PdH0.2 nanocrystals. The morphology and size of
PdH0.2 and Pd nanocrystals were measured by scanning electron microscopy
(SEM). The hydrodynamic size was measured on a Malvern Zetasizer Nano ZS90
equipped with a solid-state He-Ne laser (λ= 633 nm). The phase structures of
PdH0.2 and Pd nanocrystals were characterized by powder XRD using a M21X
diffractometer (Cu Kα, λ= 1.54056 Å) operated at 40 kV and 200 mA. The
experimental diffraction patterns were collected with a scanning range of 5°−80° at
room temperature. The composition of PdH0.2 nanocrystals was tested by an
attenuated total reflectance Fourier transform infrared spectroscopy (ATR-FTIR).
Concentrated sample solutions were dropped on the universal diamond ATR
sampling accessory and slowly dried by blowing with nitrogen gas. FTIR spectra
were then collected on a Thermo-Nicolet Nexus 670 ATR-IR spectrometer. The
UV absorption spectra of the solution (200–1100 nm) were recorded at room
temperature on a Genesys 10 s UV–visible (Vis) spectrophotometer (Thermo Sci.).
Measurement of hydrogen release behaviour of the PdH0.2 nanocrystals by
in-time UV and XRD monitorings. As to the UV monitoring, 3 mL 0.04 mgmL−1
PdH0.2 nanocrystal solution was placed into the cuvette, the solution was irradia-
tedn using an 808 nm NIR laser (1W cm−2), and we immediately measured the
UV spectra of the solution once every minute. From the change of the UV spectra
(the band intensity below 410 nm increased firstly (Supplementary Fig. 2a) and
then decreased (Supplementary Fig. 2b) with hydrogen release), we primarily
decided that there could be a critical intermediate phase (PdHc). Therefore, the
decomposition process of PdH0.2 was divided into two steps. According to the in-
time detected UV data (Fig. 2a), the release percentage of hydrogen can be cal-
culated (see Supplementary Discussion for calculation details), and plotted as a
function of reaction time, as shown in Fig. 2b. In addition, the stability of PdH0.2
nanocrystals was evaluated by in-time UV monitoring for 48 h in the absence of
NIR irradiation.
As to the XRD monitoring, PdH0.2 nanocrystals were uniformly coated on the
sample plate by dropping and drying their ethanol solution. The sample plate was
continuously irradiated by the 808 nm NIR laser (1W cm−2). Meanwhile, a
cascade of XRD patterns was collected (Fig. 2e). The interplanar spacing distance
(d) was calculated according to the Bragg equation: 2dsinθ= nλ (λ= 0.154178 nm,
n= 1, 2, 3…). Then, the unit cell parameter (a) could be obtained by the following
equation: a= d(h2+ k2+ l2)1/2 (note that this equation applies to face-centred
cubic crystals like our Pd crystals). The change in the unit cell parameter with time
(Fig. 2f) was used to determine the crystal structure shrinking and the escape/
release of hydrogen from the lattice of PdH0.2.
Measurement of the release of reductive hydrogen from the PdH0.2 nano-
crystals in PBS using the MB probe. Blue MB can be quickly reduced into
colourless MBH2 by H2 under the catalysis of Pt nanocrystals, as shown in Sup-
plementary Fig. 4. By virtue of this feature, the MB-Pt probe is frequently used for
detection of H2 concentration according to the colour change during the hydro-
genation of MB. In this work, we found that both Pd and PdH0.2 crystals have the
similar catalytic hydrogenation effect to Pt nanocrystals, and therefore MB can be
used as the Pt-free probe to in situ detect the hydrogen release from PdH0.2
nanocrystals. The reduction in the absorbance at 664 nm (the most characteristic
peak of MB) is linearly related to the amount of H2. Therefore, the standard curve
of the MB solution was measured using the UV spectrophotometer in order to
quantify the reduction of MB and the release of H2, as shown in Supplementary
Fig. 5. The detection measurement was executed according to a typical process as
follows. Firstly, the MB probe solution (300 μg mL−1) was prepared. Then PdH0.2
nanocrystals (final 4 μg mL−1) were dispersed into the MB probe solution (final
3 mL) in a cuvette, which was monitored in real time by the UV measurement. It is
noticeable that the concentration of MB should not exceed the detection range of
UV, and should also be high enough to completely absorb all released hydrogen
from PdH0.2 nanocrystals. Release experiments were divided into two groups, with
NIR irradiation and without NIR irradiation. The group with the NIR irradiation
was continuously irradiated till the balance (44 min) using the 808 nm NIR laser
(1W cm−2), and meanwhile was monitored by the UV spectrophotometer (Sup-
plementary Fig. 6a). However, the other group without the NIR irradiation was
monitored for about 33 h when the reaction was almost completed (Supplementary
Fig. 6b).
Cell culture. The mouse 4T1 breast cancer cells, B16-F10 melanoma cells, human
HeLa cervical carcinoma cells and HEK-293T emborynic kidney cells were pur-
chased from China Type Culture Collection (CTCC) obtained from the American
Type Culture Collection (ATCC). Cells were routinely tested for mycoplasma
contamination using MycoSET Mycoplasma real-time PCR detection Kit (Life
Technologies, Foster City, CA, USA). They were cultured in Dulbecco's modified
Eagle's medium (DMEM) with 10% (v:v) foetal bovine serum, 100 UmL−1 peni-
cillin, and 100 μg mL−1 streptomycin in an incubator (Thermo Scientific) at 37 °C
under the atmosphere of 5% CO2 and 90% relative humidity. To digest cells and
subculture, 0.25% (w:v) trypsin was used.
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Measurement of intracellular hydrogen release and bio-reducibility of the
PdH0.2 nanocrystals using the MB probe. Firstly, the other standard curve of the
MB solution at 664 nm was measured in 96-well plate using a Bio-Tek microplate
reader (Supplementary Fig. 7), which was used to quantify the intracellular
reduction of MB and the intracellular release of H2, as the absorption intensity
from microplate reader is different from that from UV spectrophotometer. HeLa
cells at the density of 1 × 104 cells/well were plated in a 96-well plate and cultivated
with a DMEM culture medium containing 10% foetal bovine serum at 37 °C in a
humidified and 5% CO2 incubator. After incubation for 24 h in 100 μL culture
medium per well, the culture medium was replaced with fresh one containing the
MB probe. After incubation for 1 h, the medium was replaced again with fresh one
containing the PdH0.2 nanocrystals at the concentration of 100 μg mL−1. Then, one
part of the 96-well plate was irradiated with the NIR laser of 1W cm−2, and
another part kept in the dark environment as the control. The next whole process
was monitored in real time using the Bio-Tek multi-mode microplate reader
(absorption wavelength: 664 nm) and using the microscopy (Supplementary Fig. 9).
Measurement of the ROS level in cells. HeLa or HEK-293T cells at the density of
1 × 104 cells were plated in each well of the 96-well plate and cultivated with the
DMEM culture medium containing 10% foetal bovine serum at 37 °C in a humi-
dified and 5% CO2 incubator. After incubation for 24 h in 100 μL culture medium
per well, the culture medium was replaced with fresh ones containing the PdH0.2
nanocrystals at final concentrations of 12.5–200 μg mL−1. After incubation for 1 h,
the wells at the concentration of 200 μg mL−1 and 100 μg mL−1 (as the experiment
group) were irradiated with the NIR laser of 1W cm−2. The rest was kept in the
dark (as the control group). Then, 10 μL DCFH-DA was added into each well and
monitored using the Bio-Tek multi-mode microplate reader (488 nm excitation
wavelength, 525 nm emission wavelength). In addition, the wells without the
PdH0.2 nanocrystals served as the blank control (background). Experiment groups
extracted the background to obtain the normalized ROS values for indicating the
change of intracellular ROS level.
Cytotoxicity measurement of the PdH0.2 nanocrystals. The mouse 4T1 breast
cancer cells, B16-F10 melanoma cells, human HeLa cervical carcinoma cells and
HEK-293T emborynic kidney cells were purchased from CTCC obtained from the
ATCC. Cells were routinely tested for mycoplasma contamination using MycoSET
Mycoplasma real-time PCR detection Kit (Life Technologies, Foster City, CA, USA).
The cells (1 × 104 cells/well) were planted in the 96-well plate, and co-incubated
with the PdH0.2 or Pd nanocrystals at final concentrations of 12.5–200 μg mL−1
with or without the NIR irradiation. The following treatment groups (n= 8) were
used for comparison: two control groups, 3 h of incubation with PBS or Pd
nanocrystals without the NIR irradiation; only PTT therapy group, 3 h of incubation
with Pd nanocrystals with the 808 nm NIR irradiation at 1.0 or 0.2W cm−2 for
10min each well; only hydrogen therapy group, 3 h of incubation with PdH0.2
nanocrystals without the NIR irradiation; combined hydrogenothermal therapy
group, 3 h of incubation with PdH0.2 nanocrystals with the 808 nm NIR irradiation
at 1.0 or 0.2W cm−2 for 10 min each well. After incubation for 24 h, the cellular
viability was tested by the CCK-8 method. Mean value and error bar were defined as
mean and s.d., respectively.
Photothermal effects of Pd and PdH0.2 nanocrystals. The photothermal heating
curves were obtained by monitoring the temperature change of sample solutions
under the irradiation of 808 nm NIR laser at different power densities (0.2−1.0W
cm−2). The laser was provided by a fibre-coupled continuous semiconductor diode
laser (KS-810F-8000, Kai Site Electronic Technology Co., Ltd.) and the temperature
was recorded by a fixed-mounted thermal imaging camera (FLIR A300-series). The
photothermal conversion efficiencies (η) of Pd and PdH0.2 nanocrystals were cal-
culated using the method of Roper et al.72.
In vivo photothermal imaging (PTI). The 4T1 tumour-bearing mice model was
established by injecting 1 × 107 4T1 cells into the hind limb of each female BALB/c
mouse (~20 g, purchased from Guangdong Medical Laboratory Animal Center).
After the mean volume of the tumours reached about 100 mm3, two experienced
researchers randomly divided the mice into three groups (n= 3 per group). The
tumour-bearing mice were injected with 100 μL of PBS (group 1) or 10 mg kg−1 Pd
nanocrystals (group 2) or 10 mg kg−1 PdH0.2 nanocrystals through the vein of tail
(group 3). After 2 h of injection, the mice were irradiated with the 808 nm laser at
1W cm−2 for 6 min. During the course of irradiation, we utilized the infrared
thermal imaging cameras (FLIR A300-series) to monitor the temperature change of
the tumour sites. Group 1 was taken as the control. The Administrative Committee
on Animal Research in Shenzhen University approved the protocols for all animal
experiments.
In vivo PAI. The 4T1 tumour-bearing mice model was established by injecting 1 ×
107 4T1 cells into the hind limb of each female BALB/c mouse (~20 g, purchased
from Guangdong Medical Laboratory Animal Center). All PAI experiments were
performed on an optoacoustic imaging system (Vevo 2100 LAZR system, Visual-
Sonic Inc.). For in vivo PAI study, the 4T1 tumour-bearing BALB/c mice were
anesthetized by inhalation of 1% isoflurane, and then injected with the PdH0.2
nanocrystals (100 μL, 2 mgmL−1) via the tail vein. In vivo PA images were col-
lected before injection and post injection at different time points (1, 2, 4, 8, 12, 24,
36 and 48 h). The average PA signal in the tumour tissue was extracted using the
Vevo Lab software.
Biodistribution analysis. The 4T1 tumour-bearing mice model was used to
measure the biodistribution of PdH0.2 nanocrystals. After the tumour volume
reached about 100 mm3, the 4T1 tumour-bearing mice were injected with 100 μL
PBS solution (10 mg kg−1) of PdH0.2 nanocrystals. Eighteen mice were selected and
each three mice were dissected separately at 1, 2, 4, 12, 24 and 48 h after drug
injection. Besides, the excretion of mice were collected and weighed in the group of
48 h. The weights of the heart, liver, spleen, lung, kidney and tumour of each mouse
were measured. Then, these organs were digested with aqua regia, heated to dry-
ness and added to a certain volume with deionized water. The quantitative analysis
of Pd element was determined by inductively coupled plasma-atomic emission
spectrometry (ICP-AES, Agilent Technologies, USA).
In vivo tumour therapy. All healthy female BALB/c mice (4 weeks old) were
purchased from Guangdong Medical Laboratory Animal Center and all the
in vivo experiments followed the protocols approved by the Animal Care and
Use Committee of the Shenzhen University. For 4T1 tumour therapy, when the
tumour size reached approximately 60−100 mm3 (designed as day 0), the
treatment was performed. Two experienced researchers randomly divided the mice
into six groups (n= 6 per group for 4T1 tumour), which were in situ injected
with 100 μL PBS without and with 808 nm laser irradiation (as two blank
controls, group 1 and group 2), 10 mg kg−1 Pd nanocrystals (as thermal therapy
control, group 3), 10 mg kg−1 PdH0.2 nanocrystals (as hydrogen therapy group,
group 4), 10 mg kg−1 Pd with 808 nm laser irradiation (as thermal therapy group,
group 5), 10 mg kg−1 PdH0.2 with 808 nm laser irradiation (as hydrogenothermal
therapy group, group 6) on days 1, 2, 3 and 8. Groups 2, 5 and 6 were treated with
808 nm laser at 0.5 or 1.0W cm−2 for 5 min at tumour sites after 1 h of injection.
The body weight and tumour size of each mouse were recorded every other day.
The mice were humanely killed after 22 days of treatment and all the tumours were
collected.
For B16-F10 tumour therapy, the B16-F10 tumour-bearing mice model was
established by injecting 1 × 107 B16-F10 cells into the hind limb of each female
BALB/c nude mouse (~15 g, purchased from Guangdong Medical Laboratory
Animal Center). When the tumour size reached approximately 60 mm3 (designed
as day 0), the treatment was performed. Two experienced researchers randomly
divided the mice into six groups (n= 6 per group), which were in situ injected
with 100 μL PBS without and with 808 nm laser irradiation (as two blank controls,
group 1 and group 2), 10 mg kg−1 Pd (as thermal therapy control, group 3),
10 mg kg−1 PdH0.2 (as hydrogen therapy group, group 4), 10 mg kg−1 Pd with
808 nm laser irradiation (as thermal therapy group, group 5), 10 mg kg−1 PdH0.2
with 808 nm laser irradiation (as hydrogenothermal therapy group, group 6) on
days 1, 2, 3 and 8. Groups 2, 5 and 6 were treated with 808 nm laser at 0.5W cm−2
for 5 min at tumour sites after 1 h of injection. The body weight and tumour size of
each mouse were recorded every other day. The nude mice were humanely killed
after 15 days of treatment and all the tumours were collected.
H&E-stained histology. For the H&E-stained histological evaluation, main organs
(heart, liver, spleeny, lung and kidney) were harvested after 3 weeks of treatment,
fixed in a 4% polyoxymethylene solution and then embedded in paraffin for the
H&E staining.
The liver/kidney function and hemotoxicity analyses. Two experienced
researchers randomly divided the BALB/c mice into 6 groups (n= 4 per group),
which were intravenously injected with 100 μL PBS (as control, group 1), 100 μL
10 mg kg−1 PdH0.2 nanocrystals (group 2), 100 μL 20mg kg−1 PdH0.2 nanocrystals
(group 3), 100 μL 75mg kg−1 PdH0.2 nanocrystals (group 4), 100 μL 250 mg kg−1
PdH0.2 nanocrystals (group 5) and 100 μL 500 mg kg−1 PdH0.2 nanocrystals (group
6). After 8 days, the blood of each mouse was taken and detected by biochemical
analyzer (iMagic-M7) and blood cell analyzer (BC-31 s, Mindray).
Cellular energy metabolism. HeLa or HEK-293T cells (3 × 104 cells/well) were
planted in the specific 24-well plate. After incubation for 4 h, another 150 μL
culture medium containing the PdH0.2 or Pd nanocrystals at the final concentration
of 100 μg mL−1 was added. To study the energy metabolism, we divided into 5
groups as follows: (1) two control groups, 24 h of incubation with culture medium
or Pd nanocrystals; (2) only PTT therapy group, 24 h of incubation with Pd
nanocrystals irradiated with the 808 nm NIR laser at 0.5 W cm−2 for 5 min per
well; (3) only hydrogen therapy group, 24 h of incubation with PdH0.2 nanocrystals
without the NIR irradiation; and (4) combined hydrogenothermal combination
therapy group, 24 h of incubation with PdH0.2 nanocrystals irradiated with the 808
nm NIR laser at 0.5W cm−2 for 5 min per well. After another 60 min of incubation
in a CO2-free incubator, the cellular energy metabolism parameters were detected
by the Extracellular Flux Analyzer (XFe 24).
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Statistical analysis. All the data were presented as means ± s.d. To test the sig-
nificance of the difference between sample groups, analysis by variance statistics
was applied and a value of P < 0.05 was considered to be statistically significant.
Data availability
The authors declare that the main data supporting the findings of this study are available
within the article and its Supplementary Information. Extra data are available from the
corresponding author upon request.
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